New ETF Book by Larry Connors - Click here to read more
RegeneRx to Offer Its Common Stock -
Scientists Report Impressive Research Results with TB4 on First Day of Thymosin Meeting -
RegeneRx Announces Offerings of Common Stock in Aggregate Amount of $4.7 Million -
RGN: Researchers Demonstrate Positive Results for TB4 Treatment in MS -
RegeneRx's TB4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model -
RegeneRx Biopharmaceuticals Inc. (RGN) Corporate Event Announcement Notice -
NYSE Amex OKs RegeneRx Plan of Compliance -
NYSE Amex Accepts RegeneRx Plan of Compliance -
RegeneRx Biopharmaceuticals announces collaboration with USAMRICD -
RegeneRx Working with U.S. Military to Test TB4 Against Exposure to Chemical Agents in the Eye -
PennyStockChaser.com: REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) Hot Stock on the Move! -
RegeneRx Receives Australian Patent for Treating Eye Disorders with TB4 -
RegeneRx Receives Listing Notice from NYSE Amex -
RegeneRx Biopharmaceuticals To Offer $600,000 Of Shares, Will Cut Employee Salaries -
TB4 Identified as Key Molecule Capable of Triggering Stem Cells to Repair Damaged Adult Heart -
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
